TrialNature medicine2025

Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.

Edmond M Kwan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.